Codex-prepared local review · editorial and translation review pending.
GLEI / INSIGHT
Longevity capital needs a milestone vocabulary
Financing capacity and clinical validation answer different questions about the sector.
Editorial and translation draft — prepared for local preview, pending human review.
The Altos launch demonstrates that cellular rejuvenation attracted substantial committed funding. Mouse reprogramming research illustrates the separate biological work still needed.
Our interpretation: a sector dashboard should distinguish financing, reproducible preclinical results, trial entry and patient outcomes. Funding can sustain difficult experiments but cannot substitute for their results. This framework helps readers assess progress without equating a large financing announcement with therapeutic readiness.